GSA Capital Partners LLP trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.4% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,180 shares of the company’s stock after selling 1,262 shares during the quarter. GSA Capital Partners LLP’s holdings in IDEXX Laboratories were worth $693,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Signaturefd LLC bought a new position in IDEXX Laboratories in the first quarter valued at approximately $105,000. Three Peaks Capital Management LLC bought a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $108,000. Optimum Investment Advisors bought a new position in shares of IDEXX Laboratories during the 1st quarter worth approximately $139,000. Cerebellum GP LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $181,000. Finally, Winthrop Advisory Group LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $206,000. Hedge funds and other institutional investors own 91.22% of the company’s stock.
Several research analysts have recently commented on IDXX shares. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 11th. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $255.00 target price for the company in a research note on Monday, June 18th. Stifel Nicolaus boosted their price target on IDEXX Laboratories from $225.00 to $260.00 and gave the company a “buy” rating in a research note on Tuesday, July 10th. Credit Suisse Group boosted their price target on IDEXX Laboratories from $255.00 to $259.00 and gave the company an “outperform” rating in a research note on Friday, August 17th. Finally, Piper Jaffray Companies boosted their price target on IDEXX Laboratories to $236.00 and gave the company an “overweight” rating in a research note on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. IDEXX Laboratories has an average rating of “Buy” and an average price target of $244.00.
In related news, Chairman Jonathan W. Ayers sold 30,000 shares of the business’s stock in a transaction on Thursday, August 23rd. The stock was sold at an average price of $245.50, for a total transaction of $7,365,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Jonathan W. Ayers sold 7,000 shares of the business’s stock in a transaction on Thursday, August 23rd. The stock was sold at an average price of $247.33, for a total value of $1,731,310.00. The disclosure for this sale can be found here. Insiders have sold a total of 70,129 shares of company stock valued at $17,159,219 in the last three months. 2.56% of the stock is owned by insiders.
NASDAQ IDXX traded down $1.87 during midday trading on Friday, hitting $229.24. The company had a trading volume of 496,510 shares, compared to its average volume of 485,773. The stock has a market capitalization of $21.62 billion, a PE ratio of 69.89, a P/E/G ratio of 2.28 and a beta of 0.64. The company has a debt-to-equity ratio of -14.77, a current ratio of 0.96 and a quick ratio of 0.73. IDEXX Laboratories, Inc. has a twelve month low of $146.09 and a twelve month high of $256.22.
IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Wednesday, August 1st. The company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.17 by $0.06. IDEXX Laboratories had a negative return on equity of 703.80% and a net margin of 14.50%. The firm had revenue of $580.75 million during the quarter, compared to analysts’ expectations of $574.68 million. During the same period in the previous year, the firm earned $0.87 EPS. The company’s quarterly revenue was up 14.1% compared to the same quarter last year. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 4.18 EPS for the current year.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Recommended Story: Google Finance Portfolio Workaround
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.